Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
  • English
    • 日本語
Evaluate Logo

navigation

  • What We Do
  • Vantage
    • News
    • Analysis
    • Policy & Pricing
    • Data Insights
    • Events
    • Medtech
    • Therapy Areas
    • About Vantage
      • Editorial team
  • Products & Services
    • Consensus Forecasts
    • Pharma
      • EvaluatePharma
      • EvaluatePharma Vision
    • Custom Solutions
    • How We Can Help You
      • Pharma and Biotech
      • Medtech
      • Financial Services
      • Management Consultancies
      • Service Providers
    • Client Success
    • Customer Testimonials
  • Thought Leadership
    • English
    • 日本語
  • About Us
    • Media Centre
      • Press Releases
      • Media Coverage
    • Executive Team
    • Vision & History
  • Careers
    • Current Vacancies
  • Contact Us
  • Sign Up for Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Policy & Pricing
    • Policy & Regulation
    • Pricing
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Clovis Oncology

Thumbnail
October 02, 2019

Esmo 2019 makes for a disappointing read-across to biotech

An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.

Thumbnail
October 01, 2019

Esmo 2019 – Clovis is running out of waves to catch

In prostate cancer Clovis could be adopting a more realistic regulatory stance with its Parp than Astrazeneca and Merck & Co. In the long run will it matter much?

Article image
Vantage logo
September 30, 2019

Esmo 2019 – A place for Parps in prostate cancer

Lynparza looks set to add a third tumour type to its label, strengthening the grip of Astrazeneca and Merck & Co on the Parp inhibitor market.

Article image
Vantage logo
September 28, 2019

Esmo 2019 – Glaxo’s Parp ambitions get a boost

The Prima trial delivers a convincing win for Glaxosmithkline’s Parp inhibitor Zejula, which looks to have a good chance of winning a broader label in ovarian cancer.

Article image
Vantage logo
September 28, 2019

Esmo 2019 – too little too late for Abbvie and veliparib?

Abbvie has finally scored a win with its Parp inhibitor, but the product will struggle to make headway – assuming it will even be filed.

Article image
Vantage logo
September 28, 2019

Esmo 2019 – Lynparza pushes Parps forward again

The Paola-1 study of Astrazeneca and Merck & Co’s Lynparza plus Avastin shows that more ovarian cancer patients can benefit from Parp inhibition, though the role of…

Article image
Vantage logo
September 23, 2019

As the heat rises, Clovis turns to radionuclides

The beleaguered drug maker has licensed a preclinical FAP-directed radiopharmaceutical, a target that has made little progress.

Article image
Vantage logo
August 14, 2019

Lynparza’s latest win sets up Astra-Glaxo battle

Success for Lynparza in first-line ovarian cancer, regardless of BRCA mutation status, could see Astrazeneca’s drug regain the upper hand against Glaxosmithkline’s…

Article image
Vantage logo
August 07, 2019

Clovis investors feel more Lynparza pressure

As Lynparza threatens Rubraca in prostate cancer, investors should now focus on whether Astra will show a benefit in the ATM-mutant patient population.

Article image
Vantage logo
June 05, 2019

Asco 2019 event analyser – low-key meeting belies some huge stock moves

Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.

Article image
Vantage logo
June 02, 2019

Asco 2019 – Polo reveals an overall survival hole

The keenly awaited study of Lynparza in pancreatic cancer maintenance fails to show much beyond its headline primary endpoint of progression-free survival.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

July 31, 2019

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

February 26, 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

View more...

Editor's Picks

Vantage logo
October 22, 2019

Shock revelation sees Biogen erase its aducanumab losses

Vantage logo
October 22, 2019

Vertex’s double cystic fibrosis surprise

Vantage logo
October 23, 2019

Bristol might play a role in front-line lung cancer after all

Vantage logo
October 23, 2019

Bloated on arrival? Biotech's weightiest new issues

Vantage logo
October 14, 2019

Uncovering biopharma’s hidden treasures

Open modal

Evaluate HQ +44-(0)20-7377-0800

Evaluate Americas +1-617-573-9450

Evaluate APAC +81 (0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

Follow Us

© Copyright 2019 Evaluate Ltd.